The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.
The US Food and Drug Administration (FDA) has granted approval for Acadia Pharmaceuticals’ Daybue Stix (trofinetide).
Sobi has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics for $950m.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback